Evolution of HCT/P Regulation

Federal oversight of human cell and tissue products developed gradually over several decades. The modern regulatory framework governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) is established primarily under 21 CFR Part 1271.

These regulations were implemented to reduce the risk of communicable disease transmission associated with certain human tissue products and to establish safeguards governing donor screening, tissue processing, and manufacturing practices.

Early Tissue Banking Oversight

Prior to the development of the current HCT/P regulatory framework, federal oversight of human tissue products primarily focused on preventing communicable disease transmission.

• Development of voluntary tissue banking standards
• Increased focus on donor screening and medical history review
• Initial federal regulatory involvement in tissue recovery and distribution

Creation of the HCT/P Regulatory Framework

The FDA implemented the HCT/P regulatory framework to establish structured safeguards governing the recovery, processing, storage, labeling, packaging, and distribution of human tissue products.

These requirements include:

• Donor eligibility determination procedures
• Establishment registration and product listing
• Manufacturing safeguards under Current Good Tissue Practice

Additional regulatory detail is provided in 21 CFR Part 1271 Subparts A–D.

Modern Regulatory Oversight

Today, the regulatory pathway governing HCT/Ps depends on whether the product satisfies criteria defined in 21 CFR 1271.10(a).

Products that meet these criteria may be regulated solely under Section 361 of the Public Health Service Act. Products that do not meet these criteria may be regulated under the biologics regulatory pathway.

Further explanation is available in the Section 361 vs Section 351 regulatory comparison.

Current Regulatory Landscape

In recent years the FDA has issued enforcement communications and guidance documents related to HCT/P regulatory interpretation.

Examples of regulatory enforcement activity can be reviewed in the FDA Warning Letters overview and the FDA enforcement landscape summary.

Educational reference only. Certain referenced materials may be regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271. Registration under 21 CFR Part 1271 does not constitute FDA approval, clearance, or evaluation of safety or effectiveness. This information is not intended to diagnose, treat, cure, or prevent any disease. For use by licensed healthcare professionals.